CPT® Code 67027

Implantation of an intravitreal drug delivery system involves the surgical placement of a device designed to release medication directly into the posterior segment of the eye. This method allows for a sustained release of therapeutic agents, which can be crucial for managing various ocular conditions. The procedure is particularly beneficial for patients suffering from diseases such as cytomegalovirus (CMV) retinitis, age-related macular degeneration, uveitis, diabetic retinopathy, and retinal venous occlusions. The implants, which can be either biodegradable or non-biodegradable, are designed to provide long-term treatment without the need for frequent injections. Non-biodegradable options include Vitrasert, which contains ganciclovir, an antiviral medication, and Retisert, which contains fluocinolone acetate, a corticosteroid. The implantation process typically occurs under local anesthesia, either in an ophthalmologist's office or a same-day surgery center. The procedure involves making a small incision in the pars plana, removing a portion of the vitreous gel, and placing the implant securely in the eye. This innovative approach not only enhances patient comfort by reducing the frequency of treatments but also improves the overall management of chronic eye conditions.